Type of Notification
regular notification
Date of Distribution
2014.06.12
WTO Country
Agency Responsible
Department of Health
Regions Affected
Canada’s Notification Authority and Enquiry Point | Autorité de notification et Point d’information du Canada Foreign Affairs, Trade and Development Canada | Affaires étrangères, Commerce et Développement Canada Technical Barriers and Regulations Division | Direction des règlements et obstacles techniques 111, promenade Sussex Drive, Ottawa, ON K1A 0G2 Canada Tel: (343) 203-4273 Fax: 613-943-0346 E-mail: enquirypoint@international.gc.ca
Notified Document Details
Notice of Consultation- Prescription Drug List (PDL): Naproxen (2 pages, in English and French)
Product
ICS Code
Covered Products
Ordonnances pour permettre la vente des ingrédients médicinaux pour usage humain (ICS: 11.120 ; HS 3004.90)
Description of Content

The purpose of this Notice of Consultation is to provide an opportunity to comment on the proposal to revise the listing for Naproxen on the Prescription Drug List (PDL). Only the human part of the PDL is proposed to be revised.

Relevant Documents

Site Web de Santé Canada: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/notice-avis-fra.php,
affiché le 4 Juin 2014 (disponible en anglais et en français)

Final Date of Comments
2014.08.18
Contact Details
La version électronique du texte réglementaire peut être téléchargée à partir de:http://www.hc-sc.gc.ca/dhp-mps/consultation/drug-medic/pdl_ldo_consult_naproxen-eng.php http://www.hc-sc.gc.ca/dhp-mps/consultation/drug-medic/pdl_ldo_consult_naproxen-fra.php
Document Online Link (EN)
Notified Under
1 0 0 0 0 0 0 0